The primary objective of the Immune Analysis Core is to establish standardized assays of cellular and humoral immune responses for the immunotherapeutic approaches being developed and tested in Individual Research Projects 1, 2 and 3 of the RPCI Ovarian Cancer SPORE. It will be also be responsible for enumerating and characterizing myeloid derived suppressor cells (MDSCs) by flow cytometry for Research Projects 4. The Core will routinely provide Ovarian Cancer SPORE investigators with high quality, state-of-the- art flow cytometry, cellular monitoring by ELISPOT, proliferation and cytotoxicity assays, and multiplex cytokine bead array.
The specific aims of the Immune Analysis Core are to: 1) Provide cell banking services for immune monitoring assays requiring viable mononuclear cells. 2) Provide state-of-the-art, multi-color, fluorescence activated cell sorting and analytical support for Individual Research Projects, Career Development and Developmental Research Projects. This includes high-speed sorting and multi-color analysis of cellular subsets. 3) Provide state-of-the-art ELISPOT, ELISA, proliferation and cytotoxicity assays for the functional characterization of antigen-specific T cell responses. 4) Provide state-of-the-art patient sample handling and assessment of immune responses, with standardized SOPs, quality assurance, quality control and data management practices to monitor assay performance and validate data quality. In addition to these established immunoassays services, the Immune Analysis Core will be instrumental in developing new methodologies and making them available to the SPORE investigators. It also has a significant educational role, working with all SPORE investigators including PI's, technicians and young investigators on their assay development, proper use of instrumentation and interpretation of their data.

Public Health Relevance

Centralization and standardization of the performance of the immunoassays will facilitate head-to-head comparisons of the immunological therapies being tested using the same outcome measures and provide for more efficient use of the SPORE's resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA159981-02
Application #
8754352
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
$87,915
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Gil, Margaret; Komorowski, Marcin P; Seshadri, Mukund et al. (2014) CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol 193:5327-37
Eng, Kevin H; Ruggeri, Christina (2014) Connecting prognostic ligand receptor signaling loops in advanced ovarian cancer. PLoS One 9:e107193
Liao, Jianqun; Qian, Feng; Tchabo, Nana et al. (2014) Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One 9:e84941
Suryawanshi, Swati; Huang, Xin; Elishaev, Esther et al. (2014) Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res 20:6163-74
Matsuzaki, Junko; Tsuji, Takemasa; Luescher, Immanuel et al. (2014) Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Cancer Immunol Res 2:341-50
Daudi, Sayeema; Eng, Kevin H; Mhawech-Fauceglia, Paulette et al. (2014) Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One 9:e104099